From last month...

Commonwealth Biotechnologies, Inc. Business Unit, Fairfax Identity Laboratories, Gains International ISO 17025 Accreditation for DNA Forensic Services

RICHMOND, Va., Dec 28, 2007 (BUSINESS WIRE) -- Fairfax Identity Laboratories (FIL), a business unit of Commonwealth Biotechnologies, Inc. (NASDAQ Capital Market:CBTE) is pleased to advise the market that it has been granted international ISO 17025 accreditation of its DNA Forensic laboratory. This certifies that FIL has been audited and has met or exceeded all of the international standards for accreditation. The certification covers forensic casework, relationship, and CODIS offender database testing. The accreditation was received from Forensic Quality Services-International (FQS-I), the country's longest established provider of ISO accreditation to forensic science testing laboratories. FIL has held FQS national accreditation since 1997. The new ISO17025 accreditation makes FIL eligible to bid on a much broader array of forensic contract opportunities both nationally and internationally.

"This accreditation is an acknowledgement of FIL's commitment to the highest standards to which we have always adhered. We look forward to continuing our service to the forensic and law enforcement communities," commented Charles Kelly, Director of FIL.

"The accreditation from FQS-I should open new doors for FIL in the international DNA Forensic testing market and establishes us as one of the elite Labs for forensic testing," added Thomas Reynolds, Executive Vice President and Business Unit Manager for FIL.

About Commonwealth Biotechnologies, Inc:

The CBI group of companies offers cutting-edge research and development products and services to the global life sciences industry. CBI now operates four distinct business units: (1) CBI Services, a discovery phase contract research organization; (2) Fairfax Identity Laboratories, a DNA reference business; (3) Mimotopes Pty, Ltd, Melbourne, Australia, a peptide and discovery chemistry business; and (4) Exelgen, Ltd, Bude, UK, a medicinal and synthetic discovery chemistry business. Collectively, CBI companies employ over 115 staff in world-class laboratories. For more information, visit CBI on the web at www.cbi-biotech.com.

About FIL:

Fairfax Identity Labs ("FIL"), a business unit of CBI, offers comprehensive genetic identity testing, including paternity, forensic, Convicted Offender DNA Index System ("CODIS") analyses and Clinical Genetic testing services. Since 1990, FIL has been at the forefront of DNA profiling techniques and innovations, and has continued to meet and exceed all industry standards. FIL is accredited by the American Association of Blood Banks, FQS-I, the New York State Department of Public Health, and is CLIA certified.

Forward Looking Statements:

Any statements contained in this release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties as identified in the CBI's filings with the Securities and Exchange Commission. These forward-looking statements are generally identifiable by use of the words "may," "will," "should," "expect," "anticipate," "estimate," "believe," "intend" or "project" or the negative thereof or other variations thereon or comparable terminology. Actual results, events or performance may differ materially. No statement herein should be considered an offer of any securities. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as the date hereof. Specifically, there can be no guarantee that Fairfax Identity Labs will receive contracts because of its new accreditation status. A number of factors, including customer demand, industry trends, armed conflict, and terrorist activities could alter these trends referenced herein. CBI undertakes no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

SOURCE: Commonwealth Biotechnologies, Inc.

Commonwealth Biotechnologies, Inc.
Dr. Paul D'Sylva
CEO
858-550-0959 Ext. 106